الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 171 |  |  |
| | | from | 171 | | |
Abstract
Retinopathy of prematurity is a global problem causing childhood blindness worldwide. It affects a substantial number of preterm infants worldwide. Although laser photocoagulation remains the gold standard for treatment, the off-label use of anti-vascular endothelial growth factor (anti-VEGF) therapy to treat retinopathy of prematurity, particularly posterior zone I disease, is increasing. The aim of this study was to assess the prognostic factors for ROP in infants receiving Ranibizumab as intravitreal injection, among prematures admitted to neonatal intensive care unit (NICU) of Mansoura university Children’s Hospital and were screened for retinopathy of prematurity then referred to Mansoura Ophthalmic Center for intravitreal injection. Our study shows that intravitreal ranibizumab injection is an effective treatment for prethreshold, threshold & aggressive posterior retinopathy of prematurity as compared to the natural history of these cases. Hypoxic ischemic encephalopathy, triplets, sepsis and blood transfusion are bad prognostic factors for cases with retinopathy of prematurity who received intravitreal ranibizumab. A long-term study is necessary to clarify whether long-term ocular or systemic side effects can occur. Furthur studies & modifications of the current screening & treatment protocols are needed to optimize the management of this growing condition. Conclusion : IVR injection is an effective treatment for prethreshold, threshold & APROP as compared to the natural history of these cases. HIE, triplets, sepsis and blood transfusion are bad prognostic factors for cases with ROP who received IVR. These factors are also related to the progression and natural history of ROP as stated in other studies.